Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9327696 | Gynecologic Oncology | 2005 | 8 Pages |
Abstract
The RGD-modified human Ad vectors appear to be less recognizable than unmodified Ad to preexisting NAbs in mouse models. RGD-modified Ad vectors also appear to elicit a relatively lower level of NAbs that may also contribute to the higher gene transduction efficiency of these modified vectors. Therefore, RGD-modified Ad vectors may be reagents of clinical utility in the context of preformed anti-Ad immunity and in the setting of repetitive dosing.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Minghui Wang, Akseli Hemminki, Gene P. Siegal, Mack N. Barnes, Igor Dmitriev, Victor Krasnykh, Bin Liu, David T. Curiel, Ronald D. Alvarez,